PepsiCo's latest earnings beat can be attributed to two key factors, CFO Hugh Johnston said Tuesday.» Read More
Jim Cramer sees that the market is in a sweet spot for earnings. With a new landscape, he's betting that these are the hot stocks to watch.
GoPro shares pared earlier gains after it projected unexpectedly weak first-quarter profit and announced the departure of one of its executives.
Pandora shares plummeted after the company reported quarterly revenue that widely missed expectations as mobile advertising growth slowed.
Twitter announced its fourth-quarter earnings on Thursday, surpassing analyst expectations on the top and the bottom.
AstraZeneca reported a loss for the fourth quarter of 2014, but stressed that it was on track to return to growth by 2017.
A steady recovery in Europe helped Vodafone to stem the rate of sales decline in its third quarter.
The parent of KFC and Pizza Hut missed earnings estimates, but its China sales topped estimates.
Keurig Green Mountain shares reeled after the company reported quarterly revenue that fell short of Wall Street expectations.
The results did not meet Wall Street expectations, and its shares dropped in premarket trade.
Gilead Sciences posted strong sales of its hepatitis C drugs Harvoni and Sovaldi, sending its net profit up more than four-fold for the quarter.
A crackdown in corruption in China that has hushed the once frenzied Macau casino business took its toll on Wynn Resorts in the fourth quarter.
Automatic Data Processing on Wednesday reported fiscal second-quarter profit of $331.5 million.
Whirlpool on Wednesday said its fourth-quarter profit fell due to costs from recent acquisitions, but excluding costs, the results beat expectations.
Take-Two said it now expects adjusted revenue of $1.65 billion to $1.70 billion, up from its previous forecast of $1.4 billion to $1.5 billion.
Macy's announced on Tuesday that is would purchase beauty products retailer Bluemercury for $210 million.
Shares of Myriad Genetics plunged a day after the genetic test maker chopped its fiscal year forecast due to reimbursement delays.
Shares of GlaxoSmithKline jumped on Wednesday, despite the company posting a 3 percent fall in full-year revenue.
General Motors on Wednesday posted fourth-quarter earnings far above analysts' expectations even as recall costs hit North American profit margins.
Merck said the U.S. FDA intends to rescind its "breakthrough" designation for its experimental combination treatment for hep C.
Humana said that profit fell as it invested in the Obamacare health exchanges and health contracts, and paid for costly hepatitis C treatments.